Eckert & Ziegler Q2/2018: Increase in Revenue in all Business Segments
2018-07-31 / Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist in isotope-related applications in medicine, science and industry, generated an outstanding result of € 1.62 per share in the first half year 2018. Compared with the prior year, the Group’s earnings per share increased by € 0.39 or 31 %. The weak results from the first quarter of 2018 were thus more than compensated for. The good results showed up in all segments. In the industrial business (Isotope Products), sales in the energy sector in particular increased, and with radiopharmaceuticals, the demand for isotopic markers ensured record results. In the Radiation Therapy segment, sales of afterloaders also exceeded the previous year’s figures. Since the cyclotron division has been sold in May 2017 and income and sales from discontinued operations must be reported separately in accordance with IFRS 5, the figures about the comparable period relate only to the continuing operations.
Eckert & Ziegler attained record sales of € 81.0 million in the first half of 2018. The sales increased by € 16.2 million, or 25 %, when compared to the previous year. The Isotope Products segment — which increased its sales by € 13.6 million or 33 % to € 54.2 million due to the sales of the Gamma-Service Group acquired at the end of May 2017 and the increased demand in the energy sector — experienced the largest growth spurt within the continuing operations. Sales in the Radiation Therapy segment rose as well by € 2.0 million or 16 % to € 14.2 million, driven by good sales of afterloaders. The Radiopharma segment increased sales by 15 % to € 15.4 million. The reason for that is the increasing need for pharmaceutical radioisotopes.
The strong euro had adverse effects on the sales growth in all segments due to the adverse effects on sales made in foreign currency. Compared with the previous year, the Group lost € 4.6 million that way, so the growth after adjustment for currency effects would have totaled € 20.7 million or 32 %. Organic, real sales growth – in other words, sales adjusted for currency effects and excluding the acquisitions and disposals made in 2017 – amounted to € 11.9 million or 18 %.
Since the 2018 half-year result contains only a few extraordinary effects and the good business development included almost all of the main product groups, the Executive Board now assumes that the consolidated earnings from continuing operations will increase by at least 15 % for the fiscal year 2018 compared to the prior year. The previous target of € 2.20 therefore increases to around € 2.50 per share. Sales are expected to be at around € 160 million, assuming that the euro exchange rate does not exceed $ 1.15.
The complete financial statements can be viewed here:
About Eckert & Ziegler.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with around 800 employees, is one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine.
Press Release EZAG